Pediatric Lymphomas

This is a comprehensive textbook of Hodgkin's and non-Hodgkin's lymphomas written by leaders in the field of childhood lymphomas. It includes clinical, pathologic and molecular biology of each subtype of lymphoma. The pathology chapters are comprehensive and include excellent photographs. The book is at the level of subspecialists in pediatric hematology and oncology, radiation oncology, pediatric surgery and hematopathology.

This text provides a state-of-the-art overview on Non-Hodgkin's lymphoma (NHL) in children and adolescents. The volume is divided into seven sections, each of which focuses on a critical component of pediatric NHL, including history and epidemiology, pathology and molecular biology, disease evaluation and response, common and rare sub-types of NHL, and current and novel treatment strategies. The text also comprehensively reviews the late effects of treatment, quality of patient life, and NHL treatment in countries with limited resources. Written by experts in the field, Non-Hodgkin's Lymphoma in Childhood and Adolescence is a valuable resource for clinicians and practitioners who treat children and adolescents with NHL.

This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia.

Lymphomas account for approximately 10% of childhood malignancies. Pediatric lymphomas are typically aggressive: lymphoblastic lymphoma, Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and anaplastic large cell lymphoma (ALCL) are among the most common pediatric lymphoma subtypes. The genetic basis of these neoplasms is beginning to be understood. Lymphoblastic lymphomas arise through a variety of genetic pathways, dependent upon B- or T-progenitor origin. Aggressive B-cell lymphomas (BL and DLBCL) commonly arise secondary to errors that occur during physiologic B-cell development. BL is characterized by MYC translocation with an immunoglobulin locus enhancer. This lesion may also be present in DLBCL, particularly in children, but DLBCLs often have mutations of a variety of other genes, such as BCL6. DLBCL may be separated into germinal center B-cell-like (GCB) and activated B-cell-like groups. Pediatric DLBCL are more commonly in the GCB category than are adult DLBCL. Adult DLBCL has a tendency toward increased genomic complexity compared with pediatric DLBCL. ALCL is a T-cell lymphoma that is typically characterized by ALK fusions, most commonly with NPM. Genomic profiling has identified areas of recurrent genetic gains and losses in ALCL. Understanding the underlying genetic basis of lymphoma provides hope for the development of more targeted therapies for this group of diseases. However, further investigation of the lymphoma genome is necessary, particularly in pediatric patients.

This well-illustrated monograph presents a comprehensive description of Fine-Needle Cytology (FNC), including technical procedures and ancillary techniques, applied to the lymph node (LN). Possibilities and limitations are highlighted to produce accurate cytological diagnosis of LN and cytological criteria, and to be exploited for extra-nodal lymphoproliferative processes. The normal LN structure and corresponding cytological patterns are described. Cytological, phenotypical, and molecular features are reviewed along with diagnostic criteria for various medical conditions such as lymphadenitis and lymphadenopathies, Hodgkin and Non-Hodgkin lymphoma, pediatric lymphoadenopaties, immunodeficiency-associated lymphoproliferative disorders, extra-nodal lymphoproliferative processes, metastases, and other non-lymphomatous processes. LN-FNC requires knowledge of hemathopathology and imaging techniques, as well as dexterity with FNC performing, smearing, and material management. Rapid on-site evaluation (ROSE), the choice of ancillary techniques and molecular procedures case by case are required to produce accurate and comprehensive diagnosis. This book will help cytopathologists to conduct these tasks in various organs and clinical contexts. LN-FNC requires knowledge of hemathopathology and imaging techniques, as well as dexterity with FNC performing, smearing, and material management. Rapid on-site evaluation (ROSE), the choice of ancillary techniques and molecular procedures case by case are required to produce accurate and comprehensive diagnosis. This book will help cytopathologists to conduct these tasks in various organs and clinical contexts.

Since the late 1960s, the survival rate in children and adolescents diagnosed with cancer has steadily improved, with a corresponding decline in the cancer-specific death rate. Although the improvements in survival are encouraging, they have come at the cost of acute, chronic, and late adverse effects precipitated by the toxicities associated with the individual or combined use of different types of treatment (e.g., surgery, radiation, chemotherapy). In some cases, the impairments resulting from cancer and its treatment are severe enough to qualify a child for U.S. Social Security Administration disability benefits. At the request of Social Security Administration, Childhood Cancer and Functional Impacts Across the Care Continuum provides current information and findings and conclusions regarding the diagnosis, treatment, and prognosis of selected childhood cancers, including different types of malignant solid tumors, and the effect of those cancers on childrenâ (TM)s health and functional capacity, including the relative levels of functional limitation typically associated with the cancers and their treatment. This report also provides a summary of selected treatments currently being studied in clinical trials and identifies any limitations on the availability of these treatments, such as whether treatments are available only in certain geographic areas.